Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent ...

Another study testing sotatercept as an early intervention for pulmonary arterial hypertension (PAH) is anticipated to ...

The study emphasised a higher incidence of AEs in elderly patients (65–85 years), highlighting the need for vigilant ...

New podcasts from advocacy organization Phaware will highlight treatment advances in pulmonary hypertension tied to ...

BioMarin Pharmaceutical has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients ...

Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...

The company's oncology portfolio experienced significant growth, with KEYTRUDA being a central pillar in advancing cancer treatment approvals internationally, which substantially contributed to ...

The ZENITH trial’s results contribute to the growing body of evidence supporting WINREVAIR’s potential to change PAH treatment practices. These developments are based on a press release ...

Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining ...